NRx Pharmaceuticals Has Submitted An Investigational New Drug Application To The FDA For NRX-101 For Chronic Pain
Portfolio Pulse from Benzinga Newsdesk
NRx Pharmaceuticals has submitted an investigational new drug application to the FDA for NRX-101, a drug intended for chronic pain treatment.
August 30, 2023 | 10:49 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NRx Pharmaceuticals' submission of a new drug application to the FDA could potentially boost the company's stock in the short term.
The submission of a new drug application to the FDA is a significant step for any pharmaceutical company. If approved, NRX-101 could potentially bring in significant revenue for NRx Pharmaceuticals, which would likely have a positive impact on the company's stock. However, it's important to note that the drug is still in the investigational stage and has not yet been approved.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100